Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
Conditions
Interventions
Eleclazine
Placebo to match eleclazine
Locations
84
United States
Cardiovascular Associates of Mesa
Mesa, Arizona, United States
Long Beach Memorial Hospital
Long Beach, California, United States
Good Samaritan Hospital
Los Angeles, California, United States
Radin Cardiovascular Medical Associates
Newport Beach, California, United States
Regional Cardiology Associates
Sacramento, California, United States
South Denver Cardiology Associates, PC
Littleton, Colorado, United States
Start Date
September 1, 2014
Primary Completion Date
September 1, 2016
Completion Date
October 1, 2016
Last Updated
April 9, 2019
NCT06835491
NCT06964464
NCT06591260
NCT04394637
NCT02864771
NCT06940752
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions